Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219101 | PMC |
| http://dx.doi.org/10.34067/KID.0000000000000344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Defining Renal Recovery in Patients With Hepatorenal Syndrome-Acute Kidney Injury: Experience From North American Studies.
JGH Open
December 2024
Mallinckrodt Pharmaceuticals Bridgewater New Jersey USA.
Introduction: The degree of improvement in serum creatinine (SCr) has previously been suggested as a sensitive indicator of treatment response in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI), while HRS reversal remains the primary endpoint in clinical trials.
Methods: A total of ≥ 30% SCr improvement was analyzed as an exploratory prespecified endpoint in the CONFIRM trial. In this post hoc analysis, intent-to-treat population data from three Phase 3 studies (OT-0401, REVERSE, and CONFIRM) conducted in North America in patients with HRS-AKI were pooled to assess the incidence of > 30% improvement in SCr and its association with clinical outcomes.
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure.
Hepatol Int
November 2024
Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Background And Aim: Acute-on-chronic liver failure (ACLF) patients with hepatorenal syndrome (HRS-AKI) have limited response to vasoconstrictors and worse outcomes, requiring biomarkers for early detection.
Methods: In a prospective cohort of ACLF patients (n = 240), urine NGAL was performed in patients with the clinical diagnosis of HRS-AKI, while in a subset of patients (n = 30), a complete panel of 17 urinary biomarkers was assessed for identifying terlipressin non-response (T-NR).
Results: ACLF patients with HRS-AKI, aged 45.
Early Terlipressin for HRS-AKI in ACLF.
Dig Dis Sci
November 2024
Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India.
Comparative Mortality Rates of Vasoconstrictor Agents in the Management of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Cureus
August 2024
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Article Synopsis
- Hepatorenal syndrome (HRS) is a serious condition linked to advanced liver disease, characterized by a rapid decline in kidney function, with high mortality rates despite recent treatment advancements.
- A meta-analysis of 29 studies, selected from over 8,000, showed that vasoconstrictor agents like terlipressin can improve kidney function and reduce the need for dialysis but do not significantly lower mortality rates.
- The findings suggest that while vasoconstrictors are beneficial for managing HRS, there is a clear need for personalized treatment plans and further research to identify more effective therapies that improve survival outcomes without increasing side effects.
Article Synopsis
- Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a serious complication of chronic liver disease that leads to high rates of illness and death, and terlipressin, a vasopressin analog, shows promise in treating it by effectively managing blood pressure and reducing side effects during continuous infusion.
- This study evaluated the safety and effectiveness of administering terlipressin at a continuous rate of 4 mg/day in patients with HRS-AKI, involving 136 participants who were monitored for their response to treatment and side effects.
- Results indicated that 69.1% of patients experienced a reduction in serum creatinine levels, with an average treatment duration of 7.6 days, although 21.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!